Lung nodules

  • features:
    • Rounded opacity
    • ≤3 cm in diameter (>3 cm is considered a "mass" and malignant until proven not)
    • Surrounded by pulmonary parenchyma
    • No associated lymph node enlargement, not associated with atelectasis, hilar enlargement, pleural effusion

Solid Nodule > 8 mm

  • low/moderate probability: PET scan
    • PET neg: continued surveillance
    • PET positive: staging, resection/chemo/radiation
  • high probability: PET, then resection/chemo/radiation

Solid Nodule =< 8mm

  • usually serial CT scans

Subsolid Nodule

  • focal rounded opacity either pure ground glass (focal density with underlying lung architecture) or solid component but has >50% ground glass
  • usually premalignant disease, such as adenocarcinoma in situ
  • can be slow growing
  • growth rate 400-800 days
  • evolution of part solid nodule from adenocarcinoma in situ to invasive adenocarcinoma

management

  • compare prior xray or CT
  • if stable appearance/size 2-3 years, no further workup
  • if change in appearance, obtain CT
  • if no prior CT/xray, obtain CT to identify other lesions
  • if >0.8 cm, further management (biopsy) and surveillance
  • PET can be used if tissue diagnosis unclear
  • benign characters:
    • round appearance
    • ground glass
    • < 0.6 cm
  • malignant characters:
    • partially solid (heterogenous)
    • spiculated appearance
    • >0.8 cm upper lobe location

Certain patterns of calcification within the pulmonary nodule are strongly suggestive of benign lesions, including popcorn, concentric or laminated, central, and diffuse homogeneous calcifications. Popcorn calcification is characteristically seen on radiographic imaging in patients with pulmonary hamartoma. Eccentric calcification (area of asymmetric calcification), as well as reticular or punctate calcification, should raise suspicion for malignancy.

8/2021 notes

  • lung nodule spread: hilum to mediastinum to opposite hilum
  • make sure hilum/mediastinum not involved

Type

  • ground glass: mostly infection/inflammation
    • adenocarcinoma in situ, grow more slowly
      • PET scan not helpful
      • follow 2 year interval, watch for very long time
  • Solid: most common
  • Subsolid: most likely cancer
  • Typing: acute, subacute, chronic

Size

  • < 3 cm
  • subsolid > 5 mm

DDx

  • cancer:
    • breast: 50/50 primary breast vs lung
    • ENT: mostly lung primary
    • sarcoma: mostly lung mets
  • Infection: MRSA, fungal, aspergillosis (more ground glass from hemorrhage around nodule, halo effect)
  • rheumatolgy: RA, sarcoid, Wegener
  • benign

Management

  • high probability: PET: 30% false positive
    • biopsy: EBUS vs TTFNA (25% pneumothorax, 5% chest tube)
    • surgery resection
  • low probability: CT surveillaince 3 month to 1 year
  • intermediate: 10-60%, CT, PET, biopsy

Patients risk factor

  • age is biggest risk factor
  • smoking
  • cancer hx
  • COPD
  • FHx can be important
  • work exposure
    • asbestosis: 20-30 years latency, pleural plaque
    • BAPE: effusion, eosinophil predominant, unilateral effusion
    • construction working
    • ship building
    • brake pads
    • radon

Nodule risk factors

  • size
    • <6mm, 6-8mm, >8mm
  • border/edge
    • smooth, well circumscribed
    • lobulated: uneven growth
    • spiculated
    • corona radiata
  • calcification
    • benign: popcorn, laminar, granulomatous, central fat
    • malignant: stippled, ecentric, subsolid, ground glass
  • location: higher probability in apex

Scoring

  • solidary pulmonary nodule malignancy (SPN) risk score
    • mayo clinic: incidental solid nodule
    • Brock: nodules found on lung screen
    • Fleischner risk

Others

aVS: .lungcancerscreen and .lungcancerscreenAVS